AccuGenomics, Inc., a US-based leader in next-generation sequencing (NGS) quality standards, and 1Cell.Ai, a US-based precision oncology company (with presence in Mumbai, and Pune, India) specialising in single-cell and liquid biopsy diagnostics, have announced a strategic collaboration to deliver ultra-sensitive, clinically actionable liquid biopsy testing through their clinical laboratory in India serving cancer patients across Asia.
Under this partnership, 1Cell.Ai will integrate AccuGenomics' Accukit™ CRC/NSCLC Internal Standards into its ultra-sensitive NGS-based OncoIndx panel to provide per-sample quality control and sensitivity verification. The company expects to process tens of thousands of patient samples in the next year, significantly increasing access to high-precision cancer testing across Asia. 1Cell.Ai also plans to introduce this assay at its Foster City, California facility to support precision multi-omic testing for the United States market soon.
The Accukit™ CRC/NSCLC Internal Standards are synthetic, gene-specific quality controls that validate assay performance and ensure sensitivity for detecting clinically relevant mutations in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). By embedding internal standards within every patient sample tested, laboratories can confirm per-sample analytical accuracy, improve reproducibility, and reduce false negatives, a critical advancement in clinical NGS testing where small-variant detection directly influences patient management and therapeutic decisions.
